Pieris Pharmaceuticals (NASDAQ:PIRS) will be announcing its earnings results before the market opens on Friday, May 10th. Analysts expect the company to announce earnings of ($0.18) per share for the quarter.
Pieris Pharmaceuticals (NASDAQ:PIRS) last posted its earnings results on Monday, March 18th. The biotechnology company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.05). Pieris Pharmaceuticals had a negative return on equity of 54.54% and a negative net margin of 91.93%. The firm had revenue of $4.91 million for the quarter, compared to analyst estimates of $6.92 million. On average, analysts expect Pieris Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
NASDAQ PIRS opened at $3.11 on Thursday. Pieris Pharmaceuticals has a 52 week low of $2.39 and a 52 week high of $6.55. The firm has a market cap of $151.39 million, a PE ratio of -6.22 and a beta of 1.78.
An institutional investor recently bought a new position in Pieris Pharmaceuticals stock. Dimensional Fund Advisors LP bought a new position in shares of Pieris Pharmaceuticals Inc (NASDAQ:PIRS) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 140,637 shares of the biotechnology company’s stock, valued at approximately $374,000. Dimensional Fund Advisors LP owned approximately 0.26% of Pieris Pharmaceuticals at the end of the most recent quarter. Institutional investors own 69.74% of the company’s stock.
A number of research analysts have recently commented on the stock. Zacks Investment Research cut shares of Pieris Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, April 24th. ValuEngine cut shares of Pieris Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, April 11th. Finally, HC Wainwright reissued a “buy” rating and set a $5.00 target price on shares of Pieris Pharmaceuticals in a research report on Tuesday, March 19th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $4.13.
Pieris Pharmaceuticals Company Profile
Pieris Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids.
Featured Article: Channel Trading
Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.